Examples of other clinical studies in which it was found that a three value regime was suitable for fulfilling the task to separate two conditions are “early risk prognosis of free-flap transplant failure”, “MGMT promoter methylation for selecting glioblastoma patients into trials omitting Temozolomide”, and “diagnostic criteria for high-dimensional metabolic data in newborn screening for medium-chain acyl-CoA dehydrogenase deficiency” [22,32,33], but also with sFlt-1/PlGF ratio (<38 and >85) [34,35] and PlGF measurements alone to predict still-birth FGR (<12 and >100) [36]. Here, MGMT is linked to glioblastoma.